For example, evidence has shown that compared with NPH, insulin analogues decreases the risk of severe hypoglycemia episodes by 38% (OR 0.62, 95% CI 0.42–0.91) [4], the risk of nocturnal hypoglycemia episodes by 46% (p = 0.04) [51], the risk of hospitalization due to the first severe hypoglycemic event by 21.7% (95% CI 9.6–32.1%,p<0.001) [52], the risk of hypoglycemic coma recurrence by 36.3% (95% CI 8.9–55.5%, p = 0.014) [52], hospitalizations by 49% [53], the incidence of macrovascular complications by 48% [54], and annual costs [55]. Here, INS is linked to Hypoglycemia.